IGC Pharma (IGC) Total Current Liabilities (2011 - 2026)
IGC Pharma (IGC) posted quarterly Total Current Liabilities of $2.9 million for Q1 2026, up 27.29% year-over-year from $2.3 million in Q1 2025, and up 33.26% quarter-over-quarter from $2.2 million in Q4 2025.
IGC Pharma (IGC) Total Current Liabilities (2011 - 2026) Analysis & Trends
IGC Pharma (IGC) has reported Total Current Liabilities for 16 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities rose 27.29% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (up 27.29% YoY), while the FY2026 annual figure was $2.9 million, up 27.29% from the prior year.
- Total Current Liabilities rose to $2.9 million in Q1 2026 per IGC's latest filing, from $2.2 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $2.9 million in Q1 2026 and bottomed at $1.4 million in Q4 2022.
- Historically, Total Current Liabilities has averaged $2.1 million across 5 years, with a median of $2.1 million in 2023.
- Annual changes were most pronounced in 2023 — Total Current Liabilities surged 52.39% — and 2025, when it sank 45.97%.
- IGC Pharma's Total Current Liabilities stood at $1.4 million in 2022, then soared by 42.77% to $1.9 million in 2023, then surged by 37.24% to $2.7 million in 2024, then retreated by 18.86% to $2.2 million in 2025, then surged by 33.26% to $2.9 million in 2026.
- Business Quant data shows IGC's Total Current Liabilities at $2.9 million in Q1 2026, $2.2 million in Q4 2025, and $1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | IGC Pharma | 27.20 Mn | 26.94 Mn | - | 2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.87 Mn |
| Dec 31, 2025 | 2.16 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2025 | 1.73 Mn |
| Mar 31, 2025 | 2.26 Mn |
| Dec 31, 2024 | 2.66 Mn |
| Sep 30, 2024 | 2.80 Mn |
| Jun 30, 2024 | 2.49 Mn |
| Mar 31, 2024 | 2.34 Mn |
| Dec 31, 2023 | 1.94 Mn |
| Sep 30, 2023 | 2.11 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Mar 31, 2023 | 1.90 Mn |
| Dec 31, 2022 | 1.36 Mn |
| Sep 30, 2022 | 1.38 Mn |
| Jun 30, 2022 | 1.66 Mn |
| Mar 31, 2022 | 2.44 Mn |
| Dec 31, 2021 | 1.28 Mn |
| Sep 30, 2021 | 2.02 Mn |
| Jun 30, 2021 | 2.11 Mn |